Clinical Trials Browser

Phase 2 × Myeloproliferative Disorders × selinexor × Clear all

NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Phase 2 Not yet recruiting

Myeloproliferative Disorders